{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:58:13Z","timestamp":1787317093340,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1053\/j.akdh.2024.05.001","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T06:43:06Z","timestamp":1725259386000},"page":"408-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunosuppression in Kidney Transplant Recipients: An Update for the General Nephrologist"],"prefix":"10.1053","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1530-6665","authenticated-orcid":false,"given":"Bassam G.","family":"Abu Jawdeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0743-3947","authenticated-orcid":false,"given":"Hay Me","family":"Me","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1053\/j.akdh.2024.05.001_bib1","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/jama.272.21.1705","article-title":"The early days of transplantation","volume":"272","author":"Starzl","year":"1994","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.001_bib2","first-page":"493","article-title":"Cyclosporine in transplantation - a history of converging timelines","volume":"25","author":"Colombo","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1053\/j.akdh.2024.05.001_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/230386","article-title":"Cyclosporine: a review","volume":"2012","author":"Tedesco","year":"2012","journal-title":"J Transplant"},{"issue":"5","key":"10.1053\/j.akdh.2024.05.001_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0270-9295(03)00090-1","article-title":"Cyclosporine nephrotoxicity","volume":"23","author":"Burdmann","year":"2003","journal-title":"Semin Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2024.05.001_bib5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 2","key":"10.1053\/j.akdh.2024.05.001_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ajt.16982","article-title":"OPTN\/SRTR 2020 annual data report: kidney","volume":"22","author":"Lentine","year":"2022","journal-title":"Am J Transplant"},{"issue":"25","key":"10.1053\/j.akdh.2024.05.001_bib7","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.akdh.2024.05.001_bib8","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.001_bib9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.14504","article-title":"Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation","volume":"18","author":"Davis","year":"2018","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1053\/j.akdh.2024.05.001_bib10","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1053\/j.akdh.2024.05.001_bib11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2215\/CJN.15040920","article-title":"Long-term immunosuppression management: opportunities and uncertainties","volume":"16","author":"Wojciechowski","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2024.05.001_bib12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/TP.0b013e3181952623","article-title":"Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review","volume":"87","author":"Knight","year":"2009","journal-title":"Transplantation"},{"issue":"7","key":"10.1053\/j.akdh.2024.05.001_bib13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","article-title":"Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial","volume":"9","author":"Gaston","year":"2009","journal-title":"Am J Transplant"},{"issue":"2 Suppl 1","key":"10.1053\/j.akdh.2024.05.001_bib14","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ajt.2023.02.004","article-title":"OPTN\/SRTR 2021 annual data report: kidney","volume":"23","author":"Lentine","year":"2023","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.001_bib15","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2215\/CJN.05930615","article-title":"Approach to the highly sensitized kidney transplant candidate","volume":"11","author":"Keith","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.001_bib16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/SLA.0b013e318187d1da","article-title":"A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy","volume":"248","author":"Woodle","year":"2008","journal-title":"Ann Surg"},{"issue":"10","key":"10.1053\/j.akdh.2024.05.001_bib17","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1097\/TP.0000000000001756","article-title":"Rapid discontinuation of prednisone in kidney transplant recipients: 15-year outcomes from the university of Minnesota","volume":"101","author":"Serrano","year":"2017","journal-title":"Transplantation"},{"issue":"20","key":"10.1053\/j.akdh.2024.05.001_bib18","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"issue":"10063","key":"10.1053\/j.akdh.2024.05.001_bib19","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/S0140-6736(16)32187-0","article-title":"Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial","volume":"388","author":"Thomusch","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.akdh.2024.05.001_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-6143.2007.02057.x","article-title":"A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients","volume":"8","author":"Vincenti","year":"2008","journal-title":"Am J Transplant"},{"issue":"9768","key":"10.1053\/j.akdh.2024.05.001_bib21","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.001_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":"Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study","volume":"15","author":"Budde","year":"2015","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1053\/j.akdh.2024.05.001_bib23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"issue":"9","key":"10.1053\/j.akdh.2024.05.001_bib24","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/ajt.14215","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus","volume":"17","author":"Shihab","year":"2017","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1053\/j.akdh.2024.05.001_bib25","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data","volume":"17","author":"Qazi","year":"2017","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1053\/j.akdh.2024.05.001_bib26","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/ajt.14186","article-title":"Early conversion from calcineurin inhibitor- to everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE trial","volume":"17","author":"de Fijter","year":"2017","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1053\/j.akdh.2024.05.001_bib27","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1053\/j.akdh.2024.05.001_bib28","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"Flechner","year":"2011","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2024.05.001_bib29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2024.05.001_bib30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.001_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","article-title":"Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2024.05.001_bib32","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.001_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.akdh.2024.05.001_bib34","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study","volume":"16","author":"Durrbach","year":"2016","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.001_bib35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/ajt.15688","article-title":"Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: a prospective, randomized multicenter trial","volume":"20","author":"Woodle","year":"2020","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1053\/j.akdh.2024.05.001_bib36","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1111\/ajt.14353","article-title":"Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function","volume":"17","author":"Adams","year":"2017","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1053\/j.akdh.2024.05.001_bib37","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/ajt.16430","article-title":"Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept","volume":"21","author":"Chavarot","year":"2021","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1053\/j.akdh.2024.05.001_bib38","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from calcineurin inhibitor- to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial","volume":"32","author":"Budde","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2024.05.001_bib39","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1111\/ajt.14427","article-title":"Belatacept rescue therapy in kidney transplant recipients with vascular lesions: a case control study","volume":"17","author":"Bertrand","year":"2017","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1053\/j.akdh.2024.05.001_bib40","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/ctr.12581","article-title":"Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study","volume":"29","author":"Langone","year":"2015","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2024.05.001_bib41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007890-199608150-00002","article-title":"Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model","volume":"62","author":"Andoh","year":"1996","journal-title":"Transplantation"},{"issue":"8","key":"10.1053\/j.akdh.2024.05.001_bib42","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/j.1600-6143.2011.03667.x","article-title":"Steroids and recurrent IgA nephropathy after kidney transplantation","volume":"11","author":"Clayton","year":"2011","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1053\/j.akdh.2024.05.001_bib43","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2012.04004.x","article-title":"Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer","volume":"12","author":"Campbell","year":"2012","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1053\/j.akdh.2024.05.001_bib44","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1034\/j.1600-6143.2003.00185.x","article-title":"Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation","volume":"3","author":"Valente","year":"2003","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1053\/j.akdh.2024.05.001_bib45","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/00007890-200209270-00012","article-title":"Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients","volume":"74","author":"Langer","year":"2002","journal-title":"Transplantation"},{"issue":"2","key":"10.1053\/j.akdh.2024.05.001_bib46","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ndt\/gfn574","article-title":"Sirolimus interacts with pathways essential for podocyte integrity","volume":"24","author":"Letavernier","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.001_bib47","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41572-020-0196-7","article-title":"Podocytopathies","volume":"6","author":"Kopp","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"10.1053\/j.akdh.2024.05.001_bib48","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/TP.0b013e3182007b95","article-title":"An integrated safety profile analysis of belatacept in kidney transplant recipients","volume":"90","author":"Griny\u00f3","year":"2010","journal-title":"Transplantation"},{"issue":"2","key":"10.1053\/j.akdh.2024.05.001_bib49","doi-asserted-by":"crossref","first-page":"341","DOI":"10.21037\/tau.2017.03.07","article-title":"Belatacept: the challenges with transformational drugs","volume":"6","author":"Vincenti","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1053\/j.akdh.2024.05.001_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11951","article-title":"Qualifying a novel clinical trial endpoint (iBOX) predictive of long-term kidney transplant outcomes","volume":"36","author":"Klein","year":"2023","journal-title":"Transpl Int"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924000831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924000831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T18:21:38Z","timestamp":1728930098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813924000831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2949813924000831"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2024.05.001","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppression in Kidney Transplant Recipients: An Update for the General Nephrologist","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2024.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}